<DOC>
	<DOCNO>NCT00566800</DOCNO>
	<brief_summary>RATIONALE : Chemoprevention use certain drug keep cancer form . Erlotinib may keep esophageal cancer form patient Barrett esophagus block enzyme need cell growth . PURPOSE : This phase II trial study well erlotinib work treat patient Barrett esophagus .</brief_summary>
	<brief_title>Erlotinib Treating Patients With Barrett Esophagus</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine erlotinib hydrochloride use chemopreventive agent cause histologic regression Barrett esophagus patient high risk develop esophageal cancer associate high-grade dysplasia . Secondary - To assess whether erlotinib hydrochloride cause molecular alteration EGFR , phospho-EGFR , cyclin D1 , cdc2 , p16 , p53 , PCNA , COX-2 , ploidy Barrett esophagus high-grade dysplasia . - To establish surrogate marker chemoprevention Barrett esophagus high-grade dysplasia . - To validate histologic score Barrett dysplasia develop group . - To evaluate toxicity associate use erlotinib hydrochloride patient Barrett esophagus associate high-grade dysplasia . OUTLINE : Patients receive oral erlotinib hydrochloride daily 3 month . Patients show evidence progression cancer esophagogastroduodenoscopy ( EGD ) biopsy receive additional 3 month treatment . All patient undergo repeat EGD , biopsy , determination molecular marker ( i.e. , EGFR , phospho-EGFR , cyclin D1 , cdc2 , p16 , p53 , PCNA , COX-2 , ploidy ) . After completion study treatment , patient follow 30 day .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Barrett Esophagus</mesh_term>
	<mesh_term>Precancerous Conditions</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis Barrett esophagus highgrade dysplasia Refused surgery localize therapy highgrade dysplasia No invasive esophageal carcinoma PATIENT CHARACTERISTICS : ANC ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 10 g/dL Bilirubin normal AST ALT &lt; 3 time upper limit normal ( ULN ) Alkaline phosphatase &lt; 3 time ULN No uncontrolled medical condition Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception least 1 week completion study treatment Able swallow tablet dissolve tablet No known hypersensitivity erlotinib hydrochloride No symptom suggestive malignancy ( e.g. , weight loss vomit ) No history malignancies No uncontrolled medical psychiatric condition would preclude treatment clinical trial PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior exposure erlotinib hydrochloride No concurrent antineoplastic antitumor agent , include chemotherapy , radiotherapy , immunotherapy , hormonal therapy No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>esophageal cancer</keyword>
	<keyword>Barrett esophagus</keyword>
</DOC>